Camille Merienne
Overview
Explore the profile of Camille Merienne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
21
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Briot C, Cassier P, Fredenucci I, Ehmke A, Durupt F, Merienne C, et al.
Eur J Hosp Pharm
. 2025 Jan;
PMID: 39788699
Objectives: Acceleration of the haemostasis process after dermatological surgery predominantly relies on mechanical methods, such as the use of sutures or staples. To our knowledge, there is currently no commercialised...
2.
Lapras B, Merienne C, Eynaud E, Usseglio L, Marchand C, Medina M, et al.
Sci Rep
. 2024 Dec;
14(1):31629.
PMID: 39738265
Phage therapy uses viruses (phages) against antibiotic resistance. Tailoring treatments to specific patient strains requires stocks of various highly concentrated purified phages. It, therefore, faces challenges: titration duration and specificity...
3.
Abou Chaaya C, Ourfali S, Marchand C, Merienne C, Ruffion A, Brouzes H, et al.
Fr J Urol
. 2024 Jul;
34(13):102699.
PMID: 39038654
Introduction: Intermediate-risk (IR) Non-Muscle Invasive Bladder Cancer (NMIBC) is associated with a high rate of tumor recurrence. To improve patient outcomes, it is recommended to use adjuvant intravesical therapy, by...
4.
Jambon A, Forat M, Marchand C, Morel C, Merienne C, Filali S, et al.
Eur J Hosp Pharm
. 2024 May;
PMID: 38789246
Introduction: The COVID-19 pandemic has led to unforeseen and novel manifestations, as illustrated by the management of drug shortages through the development of hospital production of sterile pharmaceutical preparations (P2S)....
5.
Merienne C, Filali S, Marchand C, Lapras B, Paillet C, Pirot F
Eur J Pharm Sci
. 2023 May;
187:106464.
PMID: 37169099
During the early months of the COVID-19 pandemic, the international medical product supply chain was tight, causing breaks in the availability of neuromuscular blocking agents essential for the treatment of...
6.
Merienne C, Rousset M, Ducint D, Castaing N, Titier K, Molimard M, et al.
J Pharm Biomed Anal
. 2017 Dec;
150:112-120.
PMID: 29220734
Several studies have shown that therapeutic drug monitoring of tyrosine kinase inhibitors (TKI) can improve their benefit in cancer. An analytical tool has been developed in order to quantify 17...